- Home
- REFI vs STRO Comparison
REFI vs STRO Comparison
Compare REFI & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REFI
- STRO
- Stock Information
- Founded
- REFI 2021
- STRO 2003
- Country
- REFI United States
- STRO United States
- Employees
- REFI N/A
- STRO N/A
- Industry
- REFI Real Estate Investment Trusts
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- REFI Real Estate
- STRO Health Care
- Exchange
- REFI Nasdaq
- STRO Nasdaq
- Market Cap
- REFI 255.6M
- STRO 96.6M
- IPO Year
- REFI 2021
- STRO 2018
- Fundamental
- Price
- REFI $12.92
- STRO $1.05
- Analyst Decision
- REFI Strong Buy
- STRO Hold
- Analyst Count
- REFI 3
- STRO 7
- Target Price
- REFI $20.00
- STRO $1.97
- AVG Volume (30 Days)
- REFI 137.6K
- STRO 1.6M
- Earning Date
- REFI 11-04-2025
- STRO 11-10-2025
- Dividend Yield
- REFI 15.94%
- STRO N/A
- EPS Growth
- REFI N/A
- STRO N/A
- EPS
- REFI 1.84
- STRO N/A
- Revenue
- REFI $56,608,781.00
- STRO $104,473,000.00
- Revenue This Year
- REFI $11.43
- STRO $65.48
- Revenue Next Year
- REFI $4.75
- STRO N/A
- P/E Ratio
- REFI $7.03
- STRO N/A
- Revenue Growth
- REFI 2.58
- STRO N/A
- 52 Week Low
- REFI $12.00
- STRO $0.52
- 52 Week High
- REFI $16.29
- STRO $4.60
- Technical
- Relative Strength Index (RSI)
- REFI 46.23
- STRO 55.33
- Support Level
- REFI $13.04
- STRO $1.02
- Resistance Level
- REFI $13.24
- STRO $1.18
- Average True Range (ATR)
- REFI 0.23
- STRO 0.12
- MACD
- REFI 0.07
- STRO 0.02
- Stochastic Oscillator
- REFI 64.52
- STRO 51.79
About REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.